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We applaud Dr De Ridder and colleagues for a formidable piece of work in search of ‘second 
best alternative’ evidence in the absence of controlled trials.  From randomised trials of 
chemotherapy, they have matched 36 of 480 patients with 36 of 632 patients who underwent 
liver surgery.  Their five-year survivals, estimated by Kaplan Meier analysis, are of the order 
of 20% and 40% respectively. The findings are in favour of inclusion of surgical resection in 
treatment.  We write to comment on the applicability of the method and provide our 
perception of the limitations of the analysis.  We conclude that the findings fall short of 
sufficient and robust evidence in themselves, but are a valuable published source for a sample 
size calculation for a randomised controlled trial (RCT) which would be fully justified by 
their findings.(2)  
 
We have concerns about the applicability of the method in this instance.  Matching studies 
open the opportunity to working on large existing data sets with completed follow up.  For 
treatment comparisons they work best when, due to a difference in policy or availability of a 
treatment, some patients arbitrarily receive one, and some another, of two available 
treatments.  The two treated groups can be considered as two circles of a Venn diagram.  In 
the overlap are those who were treated in one way, but could have had the other.  It is not as 
trustworthy evidence as blind randomisation but it is a route to exploratory analyses. In this 
instance all patients were carefully and expertly considered for one rather than the other 
treatment. Only recognised and documented features are on the available record.  This was 
compiled in the full knowledge of whether the patients were selected for, and had a resection, 
or did not.(3) Randomisation avoids this shortcoming inherent in matching studies because it 
balances both known and unknown factors. 
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We also have concerns about the analysis.  In full knowledge of the two treatment options, a 
decision was made to include or not include resection in the management in each of 1112 
patients.  Largely due to limitations on available data this number shrank to 458 who were 
‘potentially eligible for matching’. (Fig.1a&b)  Figure 2 shows the votes of three surgeons on 
resectability among 56 patients. In an RCT risk of bias is diminished and it is tested for in a 
meta-analysis.(4) It may not have been in this study.  Were the ‘dedicated’ surgeons blinded 
to outcomes and was the whole analysis independently scrutinised?  There was disagreement 
on resectability in 20 and lack of concordance about the resection strategy in a further 19.  
Whether one expects the more rigorous use of only 17 patients where a treatment decision 
was unanimous, or accepts the authors selected 36 patients on 2/3 majority votes, it is still a 
small and highly selected sample.  These would be inadequate numbers for an RCT.   
  
The researchers provide methods and hard-won results but there is a compelling argument for  
independent readers to be allowed to interpret and draw their own conclusions.(5)   Our 
conclusion is that an RCT appears to be mandatory for this burdensome treatment.  In 27 of 
the patients at least one or more of the surgeons would now use staged procedures including 
portal vein embolization or combination with radio-frequency ablation.  RFA has been shown 
in a published RCT to confer no survival advantage: “The study shows that local tumor 
ablation by RFA in combination with systemic therapy results in an excellent survival, which 
however was also achieved in the control arm.”(6)  There have been no RCTs of liver 
resection but there have been 16 randomised comparisons of more versus less intensive 
monitoring with the express purpose of earlier detection of metastases.(7) The findings are 
consistent and exemplified in the largest (N=1202 and 1228) most recently published (2014, 
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2016) and best conducted RCTs.(8, 9)  Diagnosis of metastases is brought forward by 1-2 
years, providing more opportunities for liver resection but no survival benefit was evident. 
 
In 1992, among patient who had liver resection for colorectal metastases, five-year survival 
was of the order of 25%.  Contemporary estimates were that five-year survival was near zero 
with best alternative treatments.(10)  A published power calculation from the Mayo Clinic 
suggested that if control survival were to be set, for example, at 1% or 5%, the patient 
numbers required for an RCT would have been 36 or 74 patients respectively. (11) Scheele 
and colleagues dismissed the notion of a trial, opining that follow-up and registry studies 
made “any future demands for prospective trials on the general effectiveness of hepatic 
resection for metastastic colorectal cancer not only obsolete but unethical.”(12)  In their 
discussion De Ridder and colleagues echo that statement, concluding “On ethical grounds, a 
true randomised clinical trial comparing both treatment strategies in patients with resectable 
CRLM has not been, and will not be performed.”(1)  It should be noted that no formal or 
independent ethical consideration is referred to in support of the statements in either paper.  
In addition, since this is their practice, De Ridder and colleagues are prone to confirmation 
bias.(13)  The evidence they have worked so hard to obtain remains a ‘second best 
alternative’ gained after the passage of twenty years.  Even then it is a flawed version of its 
kind.  What we need is an RCT in the zone of uncertainty.(2)  We owe future patients 
resolution of that uncertainty.  “Call randomised trials difficult, very difficult, or nearly 
impossible to do—but please do not call them unethical. It is the uncontrolled experiments 
that perpetuate unproven and potentially harmful treatments.”(14) 
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